HCHTOG1906 Trial: Sequential vs Concurrent Immunochemotherapy for Esophageal Cancer

A randomized controlled trial enrolled 70 patients with locally advanced esophageal squamous cell carcinoma from July 2019 to June 2023. Patients were randomized to receive neoadjuvant immunochemotherapy sequentially or concurrently, with primary and secondary outcomes including pathological complete remission, adverse events, and survival. Yan Zheng published the trial results on figshare under a CC-BY-4.0 license.

Use Cases

• Compare pathological complete remission rates between sequential and concurrent administration based on the trial's primary outcome.
• Analyze the incidence of grade 3–5 treatment-related adverse events and fatal events based on safety data.
• Model survival outcomes like overall survival and disease-free survival based on the secondary outcome data.
• Evaluate the risk profiles of nausea and diarrhea associated with concurrent administration based on the reported significant differences.

Strengths

• Data originates from a prospective, randomized controlled trial, a high-quality study design.
• Includes results for 70 enrolled patients and 54 who underwent surgery, providing a defined cohort.
• Reports specific outcome rates, including a 22.2% overall pathological complete remission rate and a 14.2% incidence of grade 3–5 adverse events.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 626.6 KB document, suggesting limited scope and likely summary-level data rather than raw patient records.

Provenance

Source

figshare

Collection Method

Data collected from a randomized, controlled, open-label, phase 2 clinical trial.

Time Range

July 2019 to June 2023

Freshness

Last updated 2026-05-07 04:37:16; freshness should be verified.